HC Wainwright & Co. Reiterates Buy on Vera Therapeutics, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Vera Therapeutics (NASDAQ:VERA) and maintained a $25 price target on the stock.
December 27, 2023 | 4:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Ed Arce reiterates a Buy rating on Vera Therapeutics with a $25 price target, potentially influencing investor confidence and the stock's performance.
The reiteration of a Buy rating and the maintenance of a $25 price target by a reputable analyst could lead to increased investor confidence in VERA, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100